I Wish I Were Far From the Madding Crowd

March 10, 2010

The Breast Cancer Money-Go-Round

An older story, but it would be worth finding out how much, if anything, has changed over the last few years.

The Breast Cancer Money-Go-RoundBy Lynn Landes (AlterNet) (Oct. 23, 2002)
“Racing for the cure, but running from the cause.”
Most of the well-financed breast cancer organizations make little or no mention of the non-genetic causes of breast cancer. Go to their websites. Read their literature. These organizations don’t focus on the environmental and pharmacological causes of this epidemic because it’s a dank dark alley that leads right to their corporate sponsors.
Landes cites the Green Guide, a publication of the Green Guide Institute: “National Breast Cancer Awareness Month was established by Zeneca, a bioscience company….”  Zeneca had “sales of $8.62 billion in 1997. Forty-nine percent of Zeneca’s 1997 profits came from pesticides and other industrial chemicals, and 49 percent were from pharmaceutical sales, one-third (about $1.4 billion’s worth) of which were cancer treatment drugs.”
Landes also notes that General Electric, Rhone-Poulec, Rohm & Hass, Eli Lilly Novartis, American Cyanamid, and Dupont have all profited from both sides of the breast cancer epidemic.  She further notes that NIH and CDC have tended to side with corporate conglomerates by focusing more on the detection and cure side of the equation than on the identification and elimination of environmental causes.

Another example of the blatant conflict of interest (from the Breast Cancer Fund’s “Atrazine, Frogs and Breast Cancer“)

Dr. Tyrone Hayes at the University of California at Berkeley has spent his career examining atrazine and its effect on the growth and development of frogs. He has shown that atrazine chemically castrates and feminizes male amphibians in the wild and in the lab. He suggests that atrazine-induced deformities result from the depletion of androgens and production of estrogens, perhaps after atrazine increases the activity of aromatase.

When Dr. Hayes presents his research, he often tells this story: The maker of atrazine is Syngenta, a multi-national agrichemical corporation. Syngenta was formed in 2000, when another multi-national called Novartis merged their Crop Protection and Seeds businesses with Astra Zeneca’s Agrochemicals. What is interesting and very disturbing, he argues, is that Novartis is also the producer of Femara, the breast cancer drug discussed above. And so, Dr. Hayes points out, the very company that produces atrazine (that “turns on” aromatase, thereby increasing estrogen which can lead to breast cancer cell growth) is also producing — and selling at great profit — a medication that has the opposite effect (to “turn off” aromatase).

March 7 interview with Dr. Hayes on NPR (transcript & podcast) about the neutering effects of atrazine on male frogs.

State of the Evidence 2008 (edited by Janet Gray and published by the Breast Cancer Fund) is a report on environmental exposures linked to increased breast cancer risk.  You can download a PDF version from the Breast Cancer Fund’s website.

Rethink Pink NOW! Saner Solutions to Breast Cancer (Huffington Post, Oct. 21, 2009)

Helen Cordes discusses how the major breast cancer awareness programs avoid discussing environmental causes (as well as the impact of mammograms and mammography advice on breast cancer).

Critics such as veteran women’s health advocate and writer Barbara Ehrenreich note that AstraZeneca, long a leader in the global multi-billion-dollar breast cancer pharmaceuticals market, founded National Breast Cancer Prevention Month–the generator of Pink October frenzy–in 1985, when then-Zeneca was also in the business of making pesticides deemed “probable human carcinogens” by the EPA. NBCAM is still controlled by AstraZeneca and its single-minded ‘get-your-mammogram’ mantra echoed by cosponsoring radiological and oncology associations and cancer establishment organizations. Other breast cancer heavy-hitters such as the American Cancer Society and the Susan G. Komen Foundation are also too influenced by corporate backers, say critics such as Pink Ribbons Inc. author Samantha King and No Family History author Sabrina McCormick. The result (seen most clearly in NBCAM materials) is that breast cancer’s environmental causes are avoided or downplayed to focus instead on directives to get mammograms, stay fit, and when diagnosed, obey conventional treatment regimens. (emphasis added)

While personal actions are important, why not actually prevent cancer from developing in the first place by reducing exposure to carcinogens?  For example, benzene is defined by the National Toxicology Program as a known human carcinogen, and yet the NTP profile on benzene (see the profile for references) notes:

Benzene is used as an additive in gasoline, but it also is present naturally in gasoline, because it occurs naturally in crude oil and is a by-product of oil-refining processes. The percentage of benzene in unleaded gasoline is approximately 1% to 2% by volume.

In 2002, U.S. imports of benzene totaled over 4 billion liters (1.1
billion gallons), which greatly exceeded exports of 6 million liters (1.6 million gallons). This trend continued in 2003, during which 4.5 billion liters (1.2 billion gallons) were imported and 110 million liters (29 million gallons) were exported.

The U.S. Environmental Protection Agency’s Toxics Release Inventory listed 1,008 industrial facilities that released benzene into the environment in 2001. Reported benzene releases decreased from 34 million pounds (15,400 metric tons) in 1988 to 6 million pounds (2,700 metric tons) in 2001. In 2001, reported emissions to the air totaled 5 million pounds (2,300 metric tons), and reported discharges to surface water totaled 19,000 lb (8.6 metric tons).

And that’s just one chemical!


Create a free website or blog at WordPress.com.

%d bloggers like this: